Peg-interferon plus ribavirin in chronic hepatitis C: cost-efficacy and pharmacoutilization in clinical practice

Peg-interferon plus ribavirin in chronic hepatitis C: cost-efficacy and pharmacoutilization in clinical practice

The current standard of care for the treatment of chronic hepatitis C virus (HCV) infection is combination therapy with Peg-interferon (IFN) alpha-2a or alpha-2b type plus ribavirin (RBV). This antiviral schedule can in fact avoid the three fold mortality rates associated to untreated cases with HCV...

Full description

Bibliographic Details
Main Authors: Luisa Cavalletto, Elisabetta Bernardinello, Giulio Diodati, Enzo Raise, Angelo Gatta, Liliana Chemello
Format: Article
Language:English
Published: SEEd Medical Publishers 2008-01-01
Series:Farmeconomia: Health Economics and Therapeutic Pathways
Subjects:
chronic hepatitis c
peg-interferon (ifn)
antiviral therapy
cost-effectiveness
ribavirin
hcv
Online Access:https://journals.seedmedicalpublishers.com/index.php/FE/article/view/235

Internet

https://journals.seedmedicalpublishers.com/index.php/FE/article/view/235

Similar Items